| Identification | Back Directory | [Name]
ELND 006 | [CAS]
1333990-84-3 | [Synonyms]
ELND 006
ELND0006
ELND006 >=98% (HPLC)
2H-Pyrazolo[4,3-c]quinoline, 4-cyclopropyl-7,8-difluoro-4,5-dihydro-5-[[4-(trifluoromethyl)phenyl]sulfonyl]-, (4R)- | [Molecular Formula]
C20H14F5N3O2S | [MDL Number]
MFCD28386354 | [MOL File]
1333990-84-3.mol | [Molecular Weight]
455.4 |
| Chemical Properties | Back Directory | [storage temp. ]
2-8°C | [solubility ]
DMSO: 2mg/mL, clear | [form ]
powder | [color ]
white to beige | [Optical Rotation]
[α]/D -125 to -140°, c = 0.5 in ethanol |
| Hazard Information | Back Directory | [Uses]
ELND 006 (Compound 30) is a metabolically stable γ-secretase inhibitor designed to selectively inhibit amyloid beta (Aβ) generation while sparing Notch signaling. It was developed through a synthetic strategy emphasizing diversity and chirality. ELND 006, along with its analog ELND007 (Compound 34), progressed into human clinical trials. In preclinical studies, both compounds demonstrated effective reduction of Aβ levels in vitro and in vivo. Comparisons with other γ-secretase inhibitors like Semagacestat, Begacestat, and Avagacestat underscored their potency and specificity in lowering Aβ levels in cerebrospinal fluid (CSF) of healthy human volunteers, suggesting potential therapeutic efficacy in Alzheimer's disease[1]. | [Biological Activity]
ELND006 is an allosteric γ-secretase inhibitor th at selectively blocks amyloid-β (Aβ) over Notch production both in cell-free (Aβ IC50/Notch IC50 = 0.34 nM/6.6 nM) and cell-based assays (Aβ IC50/Notch IC50 = 1.3 nM/85 nM). ELND006 is orally available and blood-brain barrier-permeable (total/unbound conc in brain = 0.12 μM/1.0 nM0.52 μM/4.5 nM2.1 μM/18 nM and total/unbound conc in plasma = 0.031 μM/0.28 nM0.19 μM/1.7 nM0.90 μM/8.1 nM 3 h post 1310 mg/kg oral dosage in ratsrespectively)and shown to effectively reduce cortical Aβx-40 in mice in vivo (by 32%48%and 61% 3 h post 1310 mg/kg oral dosage). | [References]
[1] Discovery of (R)-4-Cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-Cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007): Metabolically Stable γ-Secretase Inhibitors that Selectively Inhibit the Production of Amyloid-β over Notch |
|
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|